We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+8.88%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.26B
AUM Growth
-$664M
Cap. Flow
-$732M
Cap. Flow %
-58.11%
Top 10 Hldgs %
59.75%
Holding
95
New
14
Increased
22
Reduced
15
Closed
35

Top Buys

Rank Stock Value
1
BIOA
BioAge Labs
BIOA
+$46.2M
2
INCY icon
Incyte
INCY
+$45.5M
3
IDYA icon
IDEAYA Biosciences
IDYA
+$22.7M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$20.7M
5
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$13.3M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$100M
2
SYK icon
Stryker
SYK
+$65.7M
3
ALGN icon
Align Technology
ALGN
+$52.8M
4
ISRG icon
Intuitive Surgical
ISRG
+$38.8M
5
EW icon
Edwards Lifesciences
EW
+$37.9M

Sector Composition

Rank Sector Weight
1 Healthcare 95.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BSX icon
26
Boston Scientific
BSX
$65.8B
$11.4M 0.9%
135,819
-35,261
-21% -$2.78M
PHVS icon
27
Pharvaris
PHVS
$2.39B
$11.1M 0.88%
600,302
-1,232
-0.2% -$22.5K
EWTX icon
28
Edgewise Therapeutics
EWTX
$4.39B
$10.3M 0.82%
384,767
-90,924
-19% -$1.81M
IMNM icon
29
Immunome
IMNM
$2.52B
$9.89M 0.79%
676,766
+21,086
+3% +$300K
GH icon
30
Guardant Health
GH
$19.5B
$9.33M 0.74%
+406,645
New +$11.5M
RVMD icon
31
Revolution Medicines
RVMD
$40.2B
$9.22M 0.73%
203,271
-251,828
-55% -$11M
INBX icon
32
Inhibrx
INBX
$1.2B
$8.39M 0.67%
536,068
+72,753
+16% +$1.02M
TGTX icon
33
TG Therapeutics
TGTX
$8.58B
$8.39M 0.67%
358,644
-1,502,633
-81% -$32.8M
JBIO
34
Jade Biosciences
JBIO
$1.22B
$7.86M 0.62%
107,391
– –
ESTA icon
35
Establishment Labs
ESTA
$2.72B
$7.85M 0.62%
181,476
-247,768
-58% -$10.8M
MRNS
36
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$7.72M 0.61%
4,386,177
+234,601
+6% +$327K
JANX icon
37
Janux Therapeutics
JANX
$935M
$7.49M 0.59%
+164,770
New +$7.17M
CABA icon
38
Cabaletta Bio
CABA
$439M
$7.24M 0.57%
1,533,883
+313,483
+26% +$1.81M
ACHV icon
39
Achieve Life Sciences
ACHV
$626M
$7.18M 0.57%
1,514,032
+125,660
+9% +$574K
KURA icon
40
Kura Oncology
KURA
$922M
$5.8M 0.46%
296,884
-528,359
-64% -$10.7M
PAHC icon
41
Phibro Animal Health
PAHC
$1.38B
$5.36M 0.43%
238,184
+1,175
+0.5% +$22.7K
ILMN icon
42
Illumina
ILMN
$29.4B
$5.3M 0.42%
+40,611
New +$5.01M
ERAS icon
43
Erasca
ERAS
$6.63B
$5.03M 0.4%
1,842,668
+143,140
+8% +$403K
IMTX icon
44
Immatics
IMTX
$1.24B
$4.41M 0.35%
386,100
-410,604
-52% -$4.86M
NARI
45
DELISTED
Inari Medical, Inc. Common Stock
NARI
$3.73M 0.3%
90,327
-65,511
-42% -$3.15M
BDX icon
46
Becton Dickinson
BDX
$43.1B
$3.66M 0.29%
+15,191
New +$3.56M
NXTC icon
47
NextCure
NXTC
$17.3M
$3.66M 0.29%
222,655
– –
TMO icon
48
Thermo Fisher Scientific
TMO
$211B
$3.57M 0.28%
+5,770
New +$3.42M
EXAS
49
DELISTED
Exact Sciences
EXAS
$2.56M 0.2%
37,637
-144,191
-79% -$8.14M
IRON icon
50
Disc Medicine
IRON
$2.83B
$2.03M 0.16%
41,352
+12,096
+41% +$568K
1
2
3 4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q3 2024 Portfolio in Review

As of Q3 2024, Sofinnova Investments held 95 positions worth $1.26B, down 35% from $1.92B the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Sofinnova Investments withdrew a net $732M in Q3 2024, closing 35 positions and reducing 15 holdings. Its most notable exit was Ascendis Pharma A/S, an estimated $100M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 82% a quarter earlier.

Against the trend, Sofinnova Investments opened a new position in BioAge Labs worth $47.9M.

  • Sofinnova Investments's largest Q3 2024 buy was BioAge Labs: 2,304,901 shares worth $47.9M.
  • Sofinnova Investments added most to IDEAYA Biosciences in Q3 2024, an estimated $22.7M increase.
  • Sofinnova Investments's biggest Q3 2024 reduction was Edwards Lifesciences, cutting an estimated $37.9M.
  • Sofinnova Investments fully exited Ascendis Pharma A/S in Q3 2024, selling an estimated $100M.
  • Sofinnova Investments's ten largest holdings make up 60% of its $1.26B portfolio in Q3 2024.
  • Sofinnova Investments opened 14 new positions and closed 35 in Q3 2024.
  • Sofinnova Investments's portfolio value fell 35% quarter-over-quarter to $1.26B.

Based on Sofinnova Investments's 13F filing for Q3 2024, filed 13 Nov 2024.